TAYLOR MARQUARDT: Open Payments
NPI 1790177731 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$512 in 20 payments from 11 companies in 2025. Trend: 2023 $282 · 2024 $261 · 2025 $512
Food & beverage: $338Education: $174
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $258 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Incyte Corporation | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
| Janssen Biotech, Inc. | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Iovance Biotherapeutics, Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $19 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $16 |
Products named: IMBRUVICA, EPKINLY, JAKAFI, LYNPARZA, EMRELIS, ERLEADA, Enhertu, DATROWAY.
Industry payments across WA — which companies pay providers there.
